Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and ...
Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
Daré Bioscience, Inc. ( NASDAQ: DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO ...
Daré Bioscience Reports Third Quarter 2024 Financial Results And Provides Company Update
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended ...
CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating
Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.
Brain Implant Startups Aim to Bring Vision Back to The Blind
Food and Drug Administration’s blessing to fast-track its vision technology, called Blindsight, through the regulatory ...
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...
Ophthalmic Imaging Equipment Pipeline Market Research 2024: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
The "Ophthalmic Imaging Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" report has been added to ...